Table of Content

1. Market Introduction and Scope
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. Executive Insights and Key Takeaways
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Product Type
2.4. Snippet by Indication
2.5. Snippet by Region
3. Dynamics
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Increasing Incidence of Cancer Cases
3.1.1.2. Rising Investment and Funding
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. High Cost of Treatment
3.1.2.2. Side Effects Associated with Treatment
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Rising Number of Clinical Trials
3.1.3.2. XX
3.1.4. Impact Analysis
4. Strategic Insights and Industry Outlook
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with the largest-selling Brand
4.1.3. Market leaders with established Product
4.2. CXO Perspectives
4.3. Latest Developments and Breakthroughs
4.4. Case Studies/Ongoing Research
4.5. Regulatory and Reimbursement Landscape
4.5.1. North America
4.5.2. Europe
4.5.3. Asia Pacific
4.5.4. Latin America
4.5.5. Middle East & Africa
4.6. Porter’s Five Forces Analysis
4.7. Supply Chain Analysis
4.8. Patent Analysis
4.9. SWOT Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
5. Cancer Immunotherapy Market, By Product Type
5.1. Introduction
5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
5.1.2. Market Attractiveness Index, By Product Type
5.2. Immune Checkpoint Inhibitors*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.2.3. Atezolizumab
5.2.4. Avelumab
5.2.5. Nivolumab
5.2.6. Pembrolizumab
5.2.7. Durvalumab
5.2.8. Ipilimumab
5.2.9. Others
5.3. Monoclonal Antibodies
5.4. Cytokines
5.5. Cancer Vaccines
5.5.1. Preventive Vaccines
5.5.2. Therapeutic Vaccines
5.6. Adoptive Cell Therapy
5.6.1. Tumor Infiltrating Lymphocyte (TIL) Therapy
5.6.2. Engineered T-Cell Receptor (TCR) Therapy
5.6.3. Chimeric Antigen Receptor (CAR) T Cell Therapy
5.6.4. Natural Killer (NK) Cell Therapy
5.7. Oncolytic Virus
5.8. Other Immunotherapies
6. Cancer Immunotherapy Market, By Indication
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
6.1.2. Market Attractiveness Index, By Indication
6.2. Non-Small Cell Lung Cancer (NSCLC)*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Melanoma
6.4. Colorectal Cancer
6.5. Renal Cell Carcinoma
6.6. Breast Cancer
6.7. Bladder Cancer
6.8. Others
7. Cancer Immunotherapy Market, By Regional Market Analysis and Growth Opportunities
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
7.1.2. Market Attractiveness Index, By Region
7.2. North America
7.2.1. Introduction
7.2.2. Key Region-Specific Dynamics
7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
7.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
7.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.2.5.1. U.S.
7.2.5.2. Canada
7.2.5.3. Mexico
7.3. Europe
7.3.1. Introduction
7.3.2. Key Region-Specific Dynamics
7.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
7.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
7.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.3.5.1. Germany
7.3.5.2. U.K.
7.3.5.3. France
7.3.5.4. Spain
7.3.5.5. Italy
7.3.5.6. Rest of Europe
7.4. Latin America
7.4.1. Introduction
7.4.2. Key Region-Specific Dynamics
7.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
7.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
7.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.4.5.1. Brazil
7.4.5.2. Argentina
7.4.5.3. Rest of Latin America
7.5. Asia-Pacific
7.5.1. Introduction
7.5.2. Key Region-Specific Dynamics
7.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
7.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
7.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.5.5.1. China
7.5.5.2. India
7.5.5.3. Japan
7.5.5.4. South Korea
7.5.5.5. Rest of Asia-Pacific
7.6. Middle East and Africa
7.6.1. Introduction
7.6.2. Key Region-Specific Dynamics
7.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
7.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8. Competitive Landscape and Market Positioning
8.1. Competitive Overview and Key Market Players
8.2. Market Share Analysis and Positioning Matrix
8.3. Strategic Partnerships, Mergers & Acquisitions
8.4. Key Developments in Product Portfolios and Innovations
8.5. Company Benchmarking
9. Company Profiles
9.1. Amgen Inc.*
9.1.1. Company Overview
9.1.2. Product Portfolio
9.1.2.1. Product Description
9.1.2.2. Product Key Performance Indicators (KPIs)
9.1.2.3. Historic and Forecasted Product Sales
9.1.2.4. Product Sales Volume
9.1.3. Financial Overview
9.1.3.1. Company Revenue
9.1.3.2. Geographical Revenue Shares
9.1.3.3. Revenue Forecasts
9.1.4. Key Developments
9.1.4.1. Mergers & Acquisitions
9.1.4.2. Key Product Development Activities
9.1.4.3. Regulatory Approvals, etc.
9.1.5. SWOT Analysis
9.2. F. Hoffmann-La Roche Ltd
9.3. Bristol-Myers Squibb Company
9.4. Merck & Co., Inc.
9.5. AstraZeneca
9.6. Pfizer Inc.
9.7. Johnson & Johnson Services, Inc.
9.8. Incyte
9.9. Dendreon Pharmaceuticals LLC.
9.10. Kite Pharma, Inc.
LIST NOT EXHAUSTIVE
10. Assumptions and Research Methodology
10.1. Data Collection Methods
10.2. Data Triangulation
10.3. Forecasting Techniques
10.4. Data Verification and Validation
11. Appendix
11.1. About Us and Services
11.2. Contact Us